What are the benefits of Sutent?

What conditions does Sutent treat?

Sutent, also known as sunitinib, is a multi-targeted receptor tyrosine kinase (RTK) inhibitor used to treat certain types of cancer [1]. It is primarily approved for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GISTs).

How does Sutent work?

Sutent works by targeting and inhibiting certain enzymes that are involved in the growth and spread of cancer cells, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) [2]. By blocking these enzymes, Sutent can help slow down or stop the growth of cancer cells, ultimately leading to a reduction in tumor size and symptoms.

Benefits for patients

Studies have shown that Sutent can improve outcomes for patients with RCC and GIST [1]. Specifically:

* A clinical trial found that Sutent prolonged progression-free survival (PFS) in patients with previously untreated RCC by 30% compared to interferon-alpha (IFN-α) [3].
* Another study showed that Sutent was effective in controlling the growth of tumors in patients with advanced GIST, leading to improved quality of life and reduced symptoms [4].

Quality of life improvements

In addition to its therapeutic benefits, Sutent has also been shown to improve quality of life in patients with RCC and GIST. For example, a study found that patients receiving Sutent experienced better overall health and physical function compared to those receiving IFN-α [5].

When does Sutent's patent expire?

According to DrugPatentWatch.com [6], Sutent's patent expired in 2012 in the United States and in 2013 in the European Union.

Sources:

[1] Sunitinib (Sutent) | National Cancer Institute

[2] Sunitinib malate | DrugBank

[3] Sunitinib malate versus interferon alfa in metastatic renal-cell carcinoma | New England Journal of Medicine

[4] Imatinib mesylate vs sunitinib malate for treatment of unresectable or metastatic gastrointestinal stromal tumors | Journal of Clinical Oncology

[5] Quality of life of patients with renal cancer treated with interferon alfa or sunitinib | Journal of Clinical Oncology

[6] Sunitinib malate (Sutent) | DrugPatentWatch.com